prohibited list comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-29. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
== Overview == The first Kickin’Inn restaurant opened in Petersham, Sydney, on 17 September 2018, after the concept was developed in Dubai in 2017. Additional locations include Bankstown RSL Club in New South Wales, Woden in Canberra (opened March 2022), and Penrith on Mulgoa Road (opened December 2022), which replaced a former Hooters site. The chain engages in community activities, such as supporting breast cancer awareness and environmental programs, and has partnered with organizations like Little Wings and the Prostate Cancer Foundation of Australia. During the COVID-19 pandemic, it provided meals to frontline workers and supported local charities. As of 2025, the chain has 25 locations across Australia, including Canberra, Melbourne, New South Wales, Adelaide, Brisbane, and Perth.. It serves Cajun-style seafood boils, with food placed directly on the table without plates. The menu includes prawns, crabs, mussels, and lobsters cooked in seasoned bags with sauces like "Sha-Bang," a mix of Cajun spices, garlic butter, and lemon pepper. Customers use gloves and bibs provided by the restaurant..
Failing to build an anti-Nazi coalition in Europe, the Soviet Union signed a non-aggression pact with Nazi Germany in 1939. However, in 1941, Germany invaded the Soviet Union in the largest land invasion in history, opening the Eastern Front of World War II. The Soviet Union played a decisive role in defeating the Axis powers as part of the Allies, while extending its sphere of influence to Central and Eastern Europe. With around 27 million casualties, it suffered the most deaths of any country in World War II. In the war's aftermath, the Soviet Union consolidated the territories occupied by the Red Army into satellite states and undertook rapid economic development, cementing its status as a superpower. Geopolitical tensions with the United States led to the Cold War. The US-led Western Bloc coalesced into the NATO military alliance in 1949, prompting the Eastern Bloc to form the Warsaw Pact in 1955. With little direct combat, the blocs engaged in ideological and proxy wars. In 1953, following Stalin's death, Nikita Khrushchev initiated a campaign of de-Stalinization, which led to ideological tensions with communist China, under Mao Zedong, and culminated in an acrimonious split. The Soviet military suppressed uprisings in East Germany, Hungary and Czechoslovakia, while the resolution of the Cuban Missile Crisis narrowly averted a global conflict. Under Leonid Brezhnev, prosperity shifted toward stagnation, although relations with the US eased. In 1985, Mikhail Gorbachev sought reform through his policies of glasnost and perestroika.
Emus were used as a source of food by indigenous Australians and early European settlers. Emus are inquisitive birds and have been known to approach humans if they see unexpected movement of a limb or piece of clothing. In the wild, they may follow and observe people. Aboriginal Australians used a variety of techniques to catch the birds, including spearing them while they drank at waterholes, catching them in nets, and attracting them by imitating their calls or by arousing their curiosity with a ball of feathers and rags dangled from a tree. The pitchuri thornapple (Duboisia hopwoodii), or some similar poisonous plant, could be used to contaminate a waterhole, after which the disoriented emus were easy to catch. Another stratagem was for the hunter to use a skin as a disguise, and the birds could be lured into a camouflaged pit trap using rags or imitation calls. Aboriginal Australians only killed emus out of necessity, and frowned on anyone who hunted them for any other reason. Every part of the carcass had some use; the fat was harvested for its valuable, multiple-use oil, the bones were shaped into knives and tools, the feathers were used for body adornment and the tendons substituted for string. The early European settlers killed emus to provide food and used their fat for fuelling lamps. They also tried to prevent them from interfering with farming or invading settlements in search of water during drought. An extreme example of this was the Emu War in Western Australia in 1932.
Sources: en.wikipedia.org
Balancing and buck passing are the main strategies for preserving the balance of power and preventing a potential hegemon's rise. Instead of balancing against an aggressor, some states instead choose to "pass the buck" whereby instead of taking action to prevent a potential rise, it will pass the responsibility on to another state. John Mearsheimer, a prominent offensive realist, claims that threatened states can take four measures to facilitate buck passing, including: seeking good diplomatic relations with the aggressor in the hope that it will divert its attention to the "buck-catcher"; maintaining cool relations with the buck-catcher so as not to get dragged into the war with the buck-catcher and as a result possibly increase positive relations with the aggressor; increasing military strength to deter the aggressive state and help it focus on the buck-catcher; and facilitating the growth in power of the intended buck-catcher. In the case that a state is an enemy with both the aggressor and the intended buck-catcher, a buck-passer can implement a bait and bleed strategy whereby the state causes two rivals to engage in a protracted war while the baiter remains on the sideline. This form of buck passing enables the state to increase in relative strength at the expense of the two rivals. Bloodletting, a further variant whereby a state does what it can to increase the cost duration of the conflict can further increase the buck-passer's relative power.
The only way around this obstacle is to run an extensive number of microfluidic reaction chambers in parallel, a novel task requiring custom-built equipment. For COVID-19 mRNA vaccines, this was the main manufacturing bottleneck. Pfizer used such a parallel approach to solve the scaling problem. After verifying that impingement jet mixers could not be directly scaled up, Pfizer made about 100 of the little mixers (each about the size of a U.S. half-dollar coin), connected them together with pumps and filters with a "maze of piping," and set up a computer system to regulate flow and pressure through the mixers. Another issue, with the large-scale use of this delivery method, is the availability of the novel lipids used to create lipid nanoparticles, especially ionizable cationic lipids. Before 2020, such lipids were manufactured in small quantities measured in grams or kilograms, and they were used for medical research and a handful of drugs for rare conditions. As the safety and efficacy of mRNA vaccines became clear in 2020, the few companies able to manufacture the requisite lipids were confronted with the challenge of scaling up production to respond to orders for several tons of lipids.
=== Isolation === Many biologically active natural compounds are derived from fungi, and guanacastepene A is one such compound. Attempts were made to characterize CR115, but CR115 did not form spores under any of the conditions tested, and no other morphological characteristics were observed that provided insight into its phylogeny. rDNA sequence analysis shows a similarity of 90% to an uncharacterized root basidiomycete. The fungal strain was cultivated in potato dextrose broth for 14–21 days. The culture was then extracted with hexane to obtain a crude extract containing nonpolar secondary metabolites. This extract was fractionated by C18 flash column chromatography using an acetonitrile/water (CH3CN/H2O) step gradient and subsequently purified by reverse-phase HPLC.
Sources: en.wikipedia.org
Peptide therapeutics are peptides or polypeptides (oligomers or short polymers of amino acids) which are used for the treatment of diseases. Naturally occurring peptides may serve as hormones, growth factors, neurotransmitters, ion channel ligands, and anti-infectives; peptide therapeutics mimic such functions. The presence of a peptide structure in a drug or chemical is not enough information to determine its effectiveness or its safety, or to draw conclusions about the overall effectiveness or safety of other substances sharing that particular structure. In 2025 and 2026, off-label peptide use and the use of unapproved peptides became popular on social media. However, these peptides have unconfirmed safety and efficacy, and are not a recognised medical treatment.
Lumen stenosis that is greater than 75% was considered the hallmark of clinically significant disease in the past because recurring episodes of angina and abnormalities in stress tests are only detectable at that particular severity of stenosis. However, clinical trials have shown that only about 14% of clinically debilitating events occur at sites with more than 75% stenosis. Most cardiovascular events involve the sudden rupture of plaque, but do not display any evident luminal narrowing. Thus, greater attention has been focused on "vulnerable plaque" since the late 1990s. Besides the traditional diagnostic methods such as angiography and stress testing, other detection techniques have been developed in the past decades for earlier detection of atherosclerotic disease. Some of the detection approaches include anatomical detection and physiological measurement. Examples of anatomical detection methods include coronary calcium scoring by CT, carotid IMT (intimal media thickness) measurement by ultrasound, and intravascular imaging techniques, such as intravascular ultrasound (IVUS), and intravascular optical coherence tomography (OCT), allowing direct visualization of atherosclerotic plaques. Other methods include blood measurements, e.g., lipoprotein subclass analysis, HbA1c, hs-CRP, and homocysteine. Both anatomic and physiologic methods allow early detection before symptoms appear, disease staging, and tracking of disease progression.
At least one more regulated transport process is involved. The stoichiometry of bone mineral basically is that of hydroxyapatite precipitating from phosphate, calcium, and water at a slightly alkaline pH:
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.